Neurology · Seattle area, WA
Neurology studies in Seattle area, WA
59 recruiting studies have a site in the Seattle area. This page includes nearby cities such as Bellevue, Kirkland, Redmond, Renton.
59 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Kirkland, WA + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2/Phase 3
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease
Biohaven Therapeutics Ltd.
- Location
- Bellevue, WA + 24 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 1
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Kite, A Gilead Company
- Location
- Seattle, WA + 4 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Pridopidine Phase 3 Study in Huntington's Disease
Prilenia
- Location
- Seattle, WA + 8 other US sites
- Eligibility basics
- Ages 23–65
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Bellevue, WA + 57 other US sites
- Eligibility basics
- Ages 18–80
- Recruiting
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
phenox Inc.
- Location
- Seattle, WA + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Seattle, WA + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Seattle, WA + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
Xenon Pharmaceuticals Inc.
- Location
- Seattle, WA + 44 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Kirkland, WA + 21 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Eli Lilly and Company
- Location
- Kirkland, WA + 29 other US sites
- Eligibility basics
- Ages 55–85
- RecruitingPhase 2
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Lighthouse Pharmaceuticals, Inc.
- Location
- Bellevue, WA + 36 other US sites
- Eligibility basics
- Ages 55–80
- RecruitingPhase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Prilenia
- Location
- Seattle, WA + 17 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
Appello Pharmaceuticals, Inc.
- Location
- Kirkland, WA + 29 other US sites
- Eligibility basics
- Ages 30–80
- RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Neuron23 Inc.
- Location
- Kirkland, WA + 43 other US sites
- Eligibility basics
- Ages 40–80
- RecruitingPhase 1
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Jazz Pharmaceuticals
- Location
- Seattle, WA + 20 other US sites
- Eligibility basics
- Ages 12–75
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Celgene
- Location
- Kirkland, WA + 13 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
MapLight Therapeutics
- Location
- Bellevue, WA + 32 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 2
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
Intra-Cellular Therapies, Inc.
- Location
- Bellevue, WA + 17 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Kirkland, WA + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Kirkland, WA + 17 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Bellevue, WA + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Bellevue, WA + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Bellevue, WA + 34 other US sites
- Eligibility basics
- Ages 18+
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.